Italia markets closed

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
3,2000+0,0300 (+0,95%)
Alla chiusura: 04:00PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,1700
Aperto3,2000
Denaro2,9000 x 100
Lettera3,4200 x 1100
Min-Max giorno3,2000 - 3,4500
Intervallo di 52 settimane1,7500 - 9,0000
Volume18.634
Media Volume2.952
Capitalizzazione8,672M
Beta (5 anni mensile)1,77
Rapporto PE (ttm)N/D
EPS (ttm)-5,3900
Prossima data utili09 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

    – Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion – CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Tisento Therapeutics, Inc. today announced the closing of the previously disclosed asset purchase agreement

  • GlobeNewswire

    Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

    CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), and that Cyclerion is in compliance with all applicable listing standards. On June 1, 2022, Cyclerion was notified by Nasdaq that it was

  • GlobeNewswire

    Cyclerion Announces Reverse Stock Split

    CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 5:00 p.m. Eastern Time on May 15, 2023. The reverse stock split was approved by the Company’s stockholders at its annual meeting of stockholders held on May 15, 2023, with the final ratio determined by the Comp